8-K filed Sep 14, 2026 at 08:37 ET
Summit Therapeutics announced via 8-K that its partner Akeso presented updated overall survival (OS) data from the Phase III HARMONi-2 trial of ivonescimab vs. pembrolizumab in PD-L1-positive advanced NSCLC at WCLC 2026. Ivonescimab demonstrated a statistically significant 27% reduction in the risk of death (HR 0.73, p=0.009) with a median OS improvement of 8.2 months (30.8 vs 22.6 months), including a strong HR of 0.58 in the PD-L1 high subgroup. This is a major positive catalyst for Summit's ivonescimab program and supports the ongoing global Phase III HARMONi-7 study, though ivonescimab remains unapproved in Summit's license territories (US, Europe).